Veterinary dermatology最新文献

{"title":"Putative Paraneoplastic Pemphigus in a Cat With T-Cell Intestinal Lymphoma.","authors":"Ekaterina Mendoza-Kuznetsova, Gisela Martinez-Romero, Hannah McAnulty, Megan Sha, Keith Linder","doi":"10.1111/vde.70052","DOIUrl":"10.1111/vde.70052","url":null,"abstract":"<p><p>Paraneoplastic pemphigus (PNP) is a rare, severe autoimmune condition. The single published feline case of PNP was associated with lymphocytic thymoma. This case report describes a cat with PNP associated with intestinal T-cell lymphoma.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":"37 3","pages":"414-418"},"PeriodicalIF":1.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147933838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Cutaneous Immunological Milieu Before and After Treatment With Meglumine Antimoniate in Dogs Naturally Affected by Leishmaniosis due to Leishmania infantum.","authors":"M Platenik, A Di Loria, L Archer, M Saridomichelakis, A S Benvenuto, D Santoro","doi":"10.1111/vde.70056","DOIUrl":"10.1111/vde.70056","url":null,"abstract":"<p><strong>Background: </strong>Canine leishmaniosis (CanL) is a zoonotic disease of variable severity. The typical immune response is driven by an exaggerated humoral immune response. Protective immunity is mediated by pro-inflammatory cytokines that enhance macrophage leishmanicidal activity.</p><p><strong>Objective: </strong>To evaluate the cutaneous and the systemic immune responses as well as the cutaneous parasitic load in affected dogs before and after 28 days of treatment with meglumine antimoniate.</p><p><strong>Animals: </strong>Twelve dogs with CanL and skin lesions, treated with meglumine antimoniate at a target dose of 100 mg/kg subcutaneously every 24 h, were prospectively enrolled.</p><p><strong>Methods and materials: </strong>Before and after 28 days of treatments, blood samples and skin biopsies were collected. Circulating levels of host defence peptides, leptin and cytokines were determined via enzyme-linked immunosorbent assay (ELISA). Paraffin-embedded skin biopsies were processed for routine immunofluorescence and positive cells were identified using commercially available anti-canine antibodies. Parasitic load also was determined via molecular methods. All variables were statistically analysed with the significance level set at 0.05.</p><p><strong>Results: </strong>Among the cutaneous cell types investigated, there was a decrease in the number of T-box transcription factor TBX21 (Tbet⁺) (p = 0.016), GATA binding protein 3 (GATA3⁺) (p = 0.016), interleukin (IL)-17A⁺ (p = 0.03) cells and neutrophils (p = 0.008) after treatment, whereas there were no significant changes in forkhead box protein P3 (FoxP3⁺) regulatory T and ionised calcium-binding adaptor molecule 1 (Iba1⁺) cells. A lack of change in serum concentration of inflammatory mediators was found. Finally, cutaneous parasitic load was significantly lower after treatment (p = 0.03).</p><p><strong>Conclusions and clinical relevance: </strong>The results of this study show that the reduction of cutaneous parasitic load after meglumine antimoniate treatment results in downregulation of innate and adaptive cutaneous inflammatory responses.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"455-463"},"PeriodicalIF":1.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tolerability and Feasibility of Minimally Invasive Canine Skin Sampling: Excellent Tolerability Meets Transcriptomic Challenges.","authors":"Ina Herrmann, Lisa B Mamo, Allison N Dickey","doi":"10.1111/vde.70044","DOIUrl":"10.1111/vde.70044","url":null,"abstract":"<p><strong>Background: </strong>Advances in transcriptomics have driven the demand for minimally invasive, reproducible and high-yield skin sampling methods, particularly for studying inflammatory skin diseases in companion animals.</p><p><strong>Hypothesis/objectives: </strong>We tested tolerability, feasibility and RNA quantity and quality of three minimally invasive skin sampling techniques.</p><p><strong>Animals: </strong>Nine privately-owned dogs, including healthy individuals and those diagnosed with canine atopic dermatitis.</p><p><strong>Materials and methods: </strong>The tolerability and feasibility of three minimally invasive skin sampling techniques-microbiopsy (MB) collection, skin-scraping (SS) and tape-stripping (TS)-were tested in a clinical setting. RNA quantity and quality (RIN) were measured. Quality control and potential contamination were evaluated during downstream RNA sequencing.</p><p><strong>Results: </strong>All techniques were well-tolerated, and sampling was feasible in a clinical setting. RNA yield and quality varied significantly. Microbiopsy and SS samples yielded low RNA quantities with poor integrity. Tape-stripping samples produced the highest RNA concentration and integrity (RIN 3.4-7.1) yet showed notable variability. Although initial sequencing quality thresholds were met, downstream transcriptomic analysis of the TS samples was limited by uneven degradation and suspected DNA contamination.</p><p><strong>Conclusions and clinical relevance: </strong>Minimally invasive skin sampling methods are feasible and well-tolerated in dogs. Among the techniques evaluated, TS showed the most potential for transcriptomic applications. However, RNA quality remains a key limitation. Further refinement in sample processing and handling is essential to improve consistency and enable reliable downstream analyses in veterinary dermatological research.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"375-385"},"PeriodicalIF":1.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145901136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fosmidomycin for the Treatment of Canine Otitis Externa: A Randomised, Double-Blinded, Controlled 'Split Body' Clinical Trial.","authors":"Lindsey E Citron, Darko Stefanovski, Youwen You, Rachel Proctor, Donna Watson, Julie Randall, Christine L Cain","doi":"10.1111/vde.70049","DOIUrl":"10.1111/vde.70049","url":null,"abstract":"<p><strong>Background: </strong>Targeted antimicrobial therapy for canine otitis externa (OE) represents an opportunity for antimicrobial stewardship. Fosmidomycin selectively inhibits the non-mevalonate pathway for isoprenoid biosynthesis utilised by canine-adapted, and not human-adapted, staphylococci.</p><p><strong>Objectives: </strong>To evaluate the safety and efficacy of fosmidomycin for treatment of bacterial OE compared with enrofloxacin.</p><p><strong>Animals: </strong>Fifteen client-owned dogs with bilateral bacterial OE were enrolled.</p><p><strong>Materials and methods: </strong>Fosmidomycin stability in solution for 28 days was confirmed before trial commencement. A 'split body' design was used: each ear canal was randomised to receive a solution of fosmidomycin or enrofloxacin applied twice daily for 28 days, combined with a tapering anti-inflammatory course of oral prednisone. Owners and investigators were blinded to treatments. Dogs were evaluated at Day (D)0, D14 and D28 with clinical scores (0-3 otitis index score [OTIS3], ear cytological results, pain) and owner assessments (pruritus scores for each ear, quality-of-life scores and a hearing questionnaire). On D28, owners and investigators assessed global treatment efficacy for each ear.</p><p><strong>Results: </strong>Treatment group did not significantly influence clinical scores; cytological scores, OTIS3 scores and pruritus scores significantly improved for both groups over the trial period. Treatment efficacy for both ears was assessed as good-to-excellent by owners and investigators for the majority of dogs. No safety concerns were identified.</p><p><strong>Conclusions and clinical relevance: </strong>Fosmidomycin and enrofloxacin performed comparably for topical treatment of bacterial otitis in this study. Fosmidomycin is a promising targeted antimicrobial for canine bacterial infections while limiting selection for antimicrobial resistance in human pathogens such as Staphylococcus aureus.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"427-436"},"PeriodicalIF":1.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146107033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Histopathological Characterisation of Sebaceous Adenitis in Affected Poodle, Poodle-Related Breeds and Japanese Akita Dogs: A Retrospective, Blinded Study.","authors":"Nejra Puvača, Nikša Lemo, Frane Banović, Andrea Gudan Kurilj","doi":"10.1111/vde.70055","DOIUrl":"10.1111/vde.70055","url":null,"abstract":"<p><strong>Background: </strong>Sebaceous adenitis (SA) is a well-documented disease in poodles and Akitas. However, no comparative histopathological studies have been conducted across breeds affected with this condition.</p><p><strong>Objectives: </strong>Herein, we describe the histopathological features of SA skin lesions in 20 Akita inu and 13 poodle dogs.</p><p><strong>Animals: </strong>Inclusion criteria were Akita inu or poodle breeds with clinical signs consistent with SA and confirmed with histopathological lesions.</p><p><strong>Materials and methods: </strong>Histopathological features of Akita inu and poodle dogs diagnosed with SA were reviewed and compared on archived skin biopsy specimens.</p><p><strong>Results: </strong>The average age of dogs diagnosed with SA was 4.6 years in Akitas and 5.5 years in poodles. Sebaceous glands lacked in 15 of 20 (75%) biopsy specimens in Akitas and eight of 13 (62%) biopsy specimens in poodles. Perifollicular inflammation was generally present in both breeds, varying from mild, predominantly lymphoplasmacytic to moderate or severe pyogranulomatous inflammation. Akitas show a higher degree of perifollicular inflammation (p < 0.0001). Epidermal hyperkeratosis was observed in all cases in both breeds, yet poodles exhibited a more severe form (p = 0.0019). Follicular infundibular orthokeratosis was observed in most cases and was significantly higher in poodles (p = 0.04). Other commonly observed lesions were superficial dermatitis, perifollicular fibrosis and follicular fronds.</p><p><strong>Conclusion and clinical relevance: </strong>Akitas exhibit more intense inflammatory changes than poodles, while poodles display more prominent hyperkeratotic changes and follicular fronds. These breed-specific features of SA warrant further investigation, as they may offer valuable insights into the pathogenesis of the disease.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"386-394"},"PeriodicalIF":1.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146214294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Treatment of Cutaneous Lupus Erythematosus in a Horse With Tacrolimus Ointment.","authors":"Hélène Dropsy, Jean-Charles Husson, Frédérique Degorce-Rubiales, Noelle Cochet-Faivre","doi":"10.1111/vde.70051","DOIUrl":"10.1111/vde.70051","url":null,"abstract":"<p><p>A 9-year-old gelding Quarter Horse with a lesion on the right upper eyelid was diagnosed with cutaneous lupus erythematosus. Clinical resolution and control of UV-induced flares were achieved with topical tacrolimus and a UV-blocking mask without adverse effects over the following 3 years.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"395-398"},"PeriodicalIF":1.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146067251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Antimicrobial Activity of a 3% Chlorhexidine/Ophytrium Mousse and Shampoo in 18 Healthy Dogs.","authors":"Matt McHale, Sonya Bettenay, Gavin K Paterson, Tim Nuttall, Victoria Robinson","doi":"10.1111/vde.70057","DOIUrl":"10.1111/vde.70057","url":null,"abstract":"<p><strong>Background: </strong>Topical antimicrobial therapy is vital for managing pyoderma yet poor compliance can affect treatment outcomes.</p><p><strong>Hypothesis/objective: </strong>To evaluate the antimicrobial activity of a 3% chlorhexidine/ophytrium shampoo at different contact times and the residual activity of a 3% chlorhexidine/ophytrium mousse against meticillin-susceptible and -resistant Staphylococcus pseudintermedius (MSSP and MRSP), Escherichia coli (EC), ESBL-producing E. coli (ESBL), Pseudomonas aeruginosa (PA), and Malassezia pachydermatis (MP) in vitro.</p><p><strong>Animals: </strong>18 privately owned dogs.</p><p><strong>Materials and methods: </strong>Dogs were treated once with the shampoo for 3, 5 and 10 min, with hair samples taken after rinsing. The mousse was applied once. Hair samples were collected at 30 min (Day [D]0) and at D2, D4, D7 and D14 post-treatment. Hair bundles were plated on Mueller-Hinton (MH) agar plates pre-inoculated with MSSP, MRSP, EC, ESBL and PA, and on supplemented MH plates pre-inoculated with MP. Zones of inhibition (ZIs) were measured after 24 h (bacteria) and 48 h (MP) incubation.</p><p><strong>Results: </strong>Shampoo-there were no significant differences in antimicrobial activity between the contact times for any of the isolates. Mousse-for all the isolates, there was significant growth inhibition compared to the negative controls on D0, D2 and D4.</p><p><strong>Conclusions and clinical relevance: </strong>Hairs exposed to the shampoo and mousse inhibited growth of all the isolates in vitro. A 3 min contact time was noninferior to 10 min for the shampoo. The mousse showed residual activity for ≥ 4 days for MSSP, MRSP, EC, PA and MP.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"345-352"},"PeriodicalIF":1.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147310881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Meticillin-Resistant Staphylococcus Pyoderma With Rifampicin in 104 Dogs: Clinical Outcomes, Adverse Effects, and Rifampicin Resistance in Nonresponders.","authors":"Tian Chee Lu, David Robson, Greg Burton","doi":"10.1111/vde.70032","DOIUrl":"10.1111/vde.70032","url":null,"abstract":"<p><strong>Background: </strong>Meticillin-resistant Staphylococcus pseudintermedius (MRSP) is often resistant to multiple antibiotics. Rifampicin is effective against most MRSP isolates, yet the potential for the development of rapid resistance raises questions regarding its suitability as an antibiotic monotherapy for MRSP pyoderma.</p><p><strong>Objectives: </strong>To describe the: (i) clinical outcome of rifampicin antibiotic monotherapy in MRSP pyoderma; (ii) frequency of adverse effects; and (iii) development of rifampicin resistance among dogs considered nonresponders to therapy.</p><p><strong>Materials and methods: </strong>A retrospective study of medical records from 1/1/2013 to 1/12/2022 of client-owned dogs with MRSP pyoderma treated with oral rifampicin as a systemic antibiotic monotherapy for 21 days.</p><p><strong>Results: </strong>104 dogs were included; 77 cases of superficial pyoderma (74%) and 27 cases of deep pyoderma (26%). The mean daily rifampicin dose was 6 mg/kg. Rifampicin was clinically effective in 86 cases (82.7%). Eleven of 18 nonresponding dogs demonstrated rapidly acquired rifampicin resistance (10.6%). Eighty-two (78.8%), 17 (16.3%), two (1.9%) and three (2.9%) dogs experienced zero, mild, moderate and severe adverse effects, respectively.</p><p><strong>Conclusions and clinical relevance: </strong>Rifampicin at 6 mg/kg is an effective and mostly well-tolerated monotherapy for treating MRSP pyoderma. However, in this study, it was associated with rapid development of resistance in ≥ 10% of treated dogs. Inadequate clinical response occurred without demonstrable resistance in 6.7% of cases. Concurrent use of ciclosporin or fluconazole with rifampicin increased the odds of severe adverse reactions.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"211-221"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145378952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bacteriophage and Fusidic Acid Have Synergistic Effect Against Meticillin-Resistant Staphylococcus pseudintermedius in Ex Vivo Canine Dermis Model.","authors":"Sarah Ehling, Elisa Peh, Hilke Oltmanns, Jessica Meissner, Sophie Kittler, Christina Puff, Jutta Verspohl, Mathias Müsken, Madeleine Plötz, Andrea Vanessa Volk","doi":"10.1111/vde.70030","DOIUrl":"10.1111/vde.70030","url":null,"abstract":"<p><strong>Background: </strong>Antimicrobial stewardship has become vital given the progressive emergence of multidrug-resistant bacteria, and novel approaches to the treatment of bacterial infections are needed. Recently, reported synergistic effects of antibacterial drugs and bacteriophage therapy have revealed promising applications for the management of meticillin-resistant staphylococcal infections.</p><p><strong>Objectives: </strong>The objective of this study was to investigate the response of meticillin-resistant Staphylococcus pseudintermedius (MRSP) to treatment with a newly isolated, lytic MRSP-specific bacteriophage. Furthermore, a postulated synergism between phage and fusidic acid was examined in a canine ex vivo dermis model.</p><p><strong>Material and methods: </strong>Skin was harvested from the lateral thorax of a euthanised dog, clipped, the subcutis removed, and epidermis cleaved via a modified salt-split technique. The ex vivo dermis model established in Franz diffusion cells was inoculated with 1 × 10⁷ colony-forming units (cfu) of a clinical MRSP strain for 16 h. Then, experimental groups were treated with phage vB_SpsS_LmqsKl44-4 at a concentration of 2 × 10⁶ plaque-forming units and fusidic acid 0.4 mg alone or in combination for an additional 8 h.</p><p><strong>Results: </strong>Histopathological results showed that colonies of MRSP reached the superficial dermis and entered hair follicles. Co-treatment with fusidic acid and phage significantly reduced the amount of MRSP after 8 h.</p><p><strong>Conclusions and clinical relevance: </strong>In conclusion, topical co-treatment with fusidic acid and a phage could be a promising approach to the treatment of canine MRSP pyoderma.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"200-210"},"PeriodicalIF":1.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12967880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145087570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Topical Emollient Plus for Canine Atopic Dermatitis: A Clinical Trial Assessing Efficacy and User Acceptance.","authors":"Beatriz Fernandes, António Caldeira Mendes, Susana Paula Alves, Vanessa Schmidt, Ana Filipa Bizarro, Marta Pinto, Hugo Pereira, Joana Marto, Ana Mafalda Lourenço","doi":"10.1111/vde.70035","DOIUrl":"10.1111/vde.70035","url":null,"abstract":"<p><strong>Background: </strong>Canine atopic dermatitis (cAD) is a common, chronic skin condition characterised by epidermal barrier dysfunction, immune dysregulation and cutaneous dysbiosis. While 'emollient plus' formulations are widely used in human atopic dermatitis (hAD), their role in cAD remains underexplored.</p><p><strong>Hypothesis/objectives: </strong>To evaluate the clinical efficacy and owner-perceived value of a novel emollient plus formulation as a co-adjuvant treatment for cAD.</p><p><strong>Animals: </strong>Twenty-one client-owned dogs with controlled, nonseasonal cAD completed the study.</p><p><strong>Materials and methods: </strong>A proof-of-concept, bench-to-bedside study was conducted over 30 days. Dogs received a once-daily application of a novel emollient plus formulation developed in-house. Clinical outcomes were assessed using pruritus Visual Analog Scale (pVAS)10 and Canine Atopic Dermatitis Extent and Severity Index (CADESI)-04 scores, alongside skin barrier function parameters (trans epidermal water loss [TEWL] and pH) at the pinnae and inguinal areas. Owners evaluated therapeutic efficacy via the Owner Global Assessment of Treatment Efficacy (OGATE) questionnaire and sensorial acceptability through a survey.</p><p><strong>Results: </strong>Significant reductions were observed in pVAS10 (4.25 ± 1.85 to 3.38 ± 1.79; p = 0.016) and CADESI-04 (24.62 ± 18.48 to 13.43 ± 7.44; p = 0.02) scores. TEWL (18.63 ± 17.33 to 9.56 ± 10.75; p = 0.049) and pH (6.07 ± 0.97 to 5.41 ± 0.71; p = 0.01) only had significant reductions at the pinnae. Owner satisfaction was exceptionally high, with 90.47% rating treatment efficacy as 'good to excellent'. The sensorial properties of the formulation also received consistently positive ratings.</p><p><strong>Conclusions and clinical relevance: </strong>This cAD-targeted emollient product demonstrated promising efficacy in reducing pruritus and skin lesions while possibly improving skin barrier function. Its favourable safety profile and high owner satisfaction suggest strong potential for routine clinical use in the management of cAD. Further controlled studies are warranted to confirm efficacy and optimised treatment protocols.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"293-305"},"PeriodicalIF":1.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12967881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145453289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}